High-Risk Factors and Therapeutic Advances in Ovarian Cancer
Among gynecologic malignancies, ovarian cancer is the most lethal, primarily due to its insidious early symptoms, lack of effective screening methods, and high risk of recurrence. It poses substantial challenges to clinical diagnosis and treatment. In recent years, the clinical application of poly A...
Saved in:
Main Authors: | Xiaoyu SHA, Weiwei ZUO, Jing GAN, Yankun LIU |
---|---|
Format: | Article |
Language: | Chinese |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-07-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1243 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01) -
Hereditary breast cancer and ovarian cancer: clinical course and treatment
by: V. V. Semiglazov, et al.
Published: (2021-03-01) -
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
by: Theresa L. Werner, et al.
Published: (2018-06-01) -
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01) -
A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)